Reporting owner · CIK 0001357522

Thompson Peter A.

SEC Form 4 history for the last 180 days across 2 companies, 12 transactions and 2 filings.

DIRAspen Neuroscience, Inc.
Open-market transaction mix50% buys1 buy · 1 sale

Period: Last 180 days

Trade dates in this period: May 27, 2026 – Nov 2, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings2Form 4 records
Buying$15.0M1 purchase
Selling$4.49k1 sale
Net value+$15.0MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Thompson Peter A. transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$15.0MView disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ASPEAspen Neuroscience, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
SIONSionna Therapeutics, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$4.49kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at Aspen Neuroscience, Inc. on Nov 2, 2026 valued at $15,000,000.

Review SEC filing
Latest sale

The insider reported a sale at Sionna Therapeutics, Inc. on May 27, 2026 valued at $4,493.49.

Review SEC filing

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202601$0$4,493.49−$4,493.49
Nov 202610$15,000,000$0+$15,000,000

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$7.50M
Median P/S size$7.50M
Direct0
Indirect12
Nov 2, 2026unknown

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

6 observations · Nov 2, 2026 – Nov 2, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 2, 20263,589,132 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 2, 2026196,541Nov 4, 2026View transaction
Nov 2, 2026839,286Nov 4, 2026View transaction
Nov 2, 20261,456,270Nov 4, 2026View transaction
Nov 2, 20262,082,013Nov 4, 2026View transaction
Nov 2, 20262,589,132Nov 4, 2026View transaction
Nov 2, 20263,589,132Nov 4, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Thompson Peter A. Insider Activity FAQ

SEC Form 4 context

Who is Thompson Peter A.?

Thompson Peter A. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001357522.

Which companies has Thompson Peter A. reported transactions for?

Aspen Neuroscience, Inc., Sionna Therapeutics, Inc., Corvus Pharmaceuticals, Inc., ALPINE IMMUNE SCIENCES, INC.

When was Thompson Peter A.'s latest insider buy?

The insider reported a buy at Aspen Neuroscience, Inc. on Nov 2, 2026 valued at $15,000,000.

When was Thompson Peter A.'s latest insider sale?

The insider reported a sale at Sionna Therapeutics, Inc. on May 27, 2026 valued at $4,493.49.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.